title: Adverse reactions to antituberculosis drugs in Manguinhos, Rio de Janeiro, Brazil.
abstract: OBJECTIVE
  This study aimed to characterize and estimate the frequency of adverse reactions to antituberculosis drugs in the population treated at the Centro de Saúde Escola Germano Sinval Faria, a primary health care clinic in Manguinhos, Rio de Janeiro City, and to explore the relationship between adverse drug reactions and some of the patients' demographic and health characteristics.
  
  
  METHODS
  This descriptive study was conducted via patient record review of incident cases between 2004 and 2008.
  
  
  RESULTS
  Of the 176 patients studied, 41.5% developed one or more adverse reactions to antituberculosis drugs, totaling 126 occurrences. The rate of adverse reactions to antituberculosis drugs was higher among women, patients aged 50 years or older, those with four or more comorbidities, and those who used five or more drugs. Of the total reactions, 71.4% were mild. The organ systems most affected were as follows: the gastrointestinal tract (29.4%), the skin and appendages (21.4%), and the central and peripheral nervous systems (14.3%). Of the patients who experienced adverse reactions to antituberculosis drugs, 65.8% received no drug treatment for their adverse reactions, and 4.1% had one of the antituberculosis drugs suspended because of adverse reactions. "Probable reactions" (75%) predominated over "possible reactions" (24%). In the study sample, 64.3% of the reactions occurred during the first two months of treatment, and most (92.6%) of the reactions were ascribed to the combination of rifampicin + isoniazid + pyrazinamide (Regimen I). A high dropout rate from tuberculosis treatment (24.4%) was also observed.
  
  
  CONCLUSIONS
  This study suggests a high rate of adverse reactions to antituberculosis drugs.
authors: Escola Nacional de Saúde Pública Sergio Arouca, Fiocruz, Rio de Janeiro, RJ, Brazil. glaucienesantana@uol.com.br
authors: Glauciene Santana
authors: GS
authors: Damasceno
authors: Lusiele
authors: L
authors: Guaraldo
authors: Elyne Montenegro
authors: EM
authors: Engstrom
authors: Mariza Miranda
authors: MM
authors: Theme Filha
authors: Reinaldo
authors: R
authors: Souza-Santos
authors: Ana Gloria Godoi
authors: AG
authors: Vasconcelos
authors: Suely
authors: S
authors: Rozenfeld
mesh_terms: D000293:Adolescent; D000328:Adult; D017677:Age Distribution; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000995:Antitubercular Agents / Q000009:adverse effects*; D001938:Brazil; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D016896:Treatment Outcome; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*; D055815:Young Adult
chemical_list: D000995:Antitubercular Agents
references: J Bras Pneumol. 2007 Jul-Aug;33(4):443-7
references: 17982537
references: Tuber Lung Dis. 1996 Feb;77(1):37-42
references: 8733412
references: Clin Pharmacol Ther. 1981 Aug;30(2):239-45
references: 7249508
references: JAMA. 1975 Dec 22;234(12):1236-41
references: 1242749
references: Pak J Pharm Sci. 2008 Jan;21(1):51-6
references: 18166520
references: Int J Tuberc Lung Dis. 2007 Aug;11(8):868-75
references: 17705952
references: J Bras Pneumol. 2008 Dec;34(12):1049-55
references: 19180340
references: Am J Respir Crit Care Med. 2003 Jun 1;167(11):1472-7
references: 12569078
references: Cad Saude Publica. 2003 May-Jun;19(3):717-24
references: 12806474
references: Eur Respir J. 1996 Oct;9(10):2026-30
references: 8902462
references: J Bras Pneumol. 2010 Mar-Apr;36(2):232-8
references: 20485945
references: World Health Organ Tech Rep Ser. 1972;498:1-25
references: 4625548
references: Thorax. 1996 Feb;51(2):132-6
references: 8711642
references: Rev Soc Bras Med Trop. 2002 Jan-Feb;35(1):51-8
references: 11873262